Haemonetics (HAE) 10-Q 6 Aug 19 2020 Q1 Quarterly report Financial data

DOCUMENT AND ENTITY INFORMATION

DOCUMENT AND ENTITY INFORMATION - shares	3 Months Ended
	Jun. 29, 2019	Aug. 02, 2019
Cover page.
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 29, 2019
Document Transition Report	false
Entity File Number	001-14041
Entity Registrant Name	HAEMONETICS CORP
Entity Central Index Key	0000313143
Current Fiscal Year End Date	--03-28
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Incorporation, State or Country Code	MA
Entity Tax Identification Number	04-2882273
Entity Address, Address Line One	400 Wood Road
Entity Address, City or Town	Braintree
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02184
City Area Code	781
Local Phone Number	848-7100
Title of 12(b) Security	Common stock, $.01 par value per share
Trading Symbol	HAE
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		50,769,875

CONSOLIDATED STATEMENTS OF LOSS

CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Jun. 29, 2019	Jun. 30, 2018
Income Statement [Abstract]
Net revenues	$ 238,451	$ 229,347
Cost of goods sold	122,545	146,103
Gross profit	115,906	83,244
Operating expenses:
Research and development	7,487	9,406
Selling, general and administrative	73,000	68,545
Impairment of assets	48,721	0
Total operating expenses	129,208	77,951
Operating (loss) income	(13,302)	5,293
Interest and other expense, net	(4,423)	(1,978)
(Loss) income before (benefit) provision for income taxes	(17,725)	3,315
(Benefit) provision for income taxes	(9,246)	6,134
Net loss	$ (8,479)	$ (2,819)
Net loss per share - basic and diluted (in dollars per share)	$ (0.17)	$ (0.05)
Weighted average shares outstanding
Basic and diluted (in shares)	51,010	52,119
Comprehensive loss	$ (12,097)	$ (7,538)

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 29, 2019	Mar. 30, 2019
Current assets:
Cash and cash equivalents	$ 190,234	$ 169,351
Accounts receivable, less allowance of $3,624 at June 29, 2019 and $3,937 at March 30, 2019	163,339	185,027
Inventories, net	221,953	194,337
Prepaid expenses and other current assets	39,752	27,406
Total current assets	615,278	576,121
Property, plant and equipment, net	276,748	343,979
Intangible assets, less accumulated amortization of $271,769 at June 29, 2019 and $263,479 at March 30, 2019	120,340	127,693
Goodwill	211,140	210,819
Deferred tax asset	4,622	4,359
Other long-term assets	31,482	11,796
Total assets	1,259,610	1,274,767
Current liabilities:
Notes payable and current maturities of long-term debt	117,548	27,666
Accounts payable	60,792	63,361
Accrued payroll and related costs	31,352	53,200
Other liabilities	83,973	91,532
Total current liabilities	293,665	235,759
Long-term debt, net of current maturities	318,144	322,454
Deferred tax liability	14,006	19,906
Other long-term liabilities	42,829	28,780
Total stockholders’ equity
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 50,771,013 shares at June 29, 2019 and 51,019,918 shares at March 30, 2019	508	510
Additional paid-in capital	525,038	536,320
Retained earnings	99,418	161,418
Accumulated other comprehensive loss	(33,998)	(30,380)
Total stockholders’ equity	590,966	667,868
Total liabilities and stockholders’ equity	$ 1,259,610	$ 1,274,767

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) $ in Thousands	Jun. 29, 2019	Mar. 30, 2019
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 3,624	$ 3,937
Intangible assets, amortization	$ 271,769	$ 263,479
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	50,771,013	51,019,918
Common stock, shares outstanding (in shares)	50,771,013	51,019,918

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY Statement - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income/(Loss)
Balance (in shares) at Mar. 31, 2018		52,343
Balance at Mar. 31, 2018	$ 752,429	$ 523	$ 503,955	$ 266,942	$ (18,991)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan (in shares)		45
Employee stock purchase plan	1,780	$ 1	1,779
Exercise of stock options (in shares)		75
Exercise of stock options	2,831	$ 1	2,830
Shares repurchased (in shares)		(888)
Shares repurchased	(80,000)	$ (9)	(4,552)	(75,439)
Issuance of restricted stock, net of cancellations (in shares)		67
Issuance of restricted stock, net of cancellations	0
Share-based compensation expense	3,379		3,379
Cumulative effect of change in accounting standards	1,177			1,177
Net loss	(2,819)			(2,819)
Other comprehensive income (loss)	(4,719)				(4,719)
Balance (in shares) at Jun. 30, 2018		51,642
Balance at Jun. 30, 2018	674,058	$ 516	507,391	189,861	(23,710)
Balance (in shares) at Mar. 30, 2019		51,020
Balance at Mar. 30, 2019	667,868	$ 510	536,320	161,418	(30,380)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan (in shares)		25
Employee stock purchase plan	1,830	$ 0	1,830
Exercise of stock options (in shares)		85
Exercise of stock options	3,635	$ 1	3,634
Shares repurchased (in shares)		(616)
Shares repurchased	(75,000)	$ (6)	(21,473)	(53,521)
Issuance of restricted stock, net of cancellations (in shares)		257
Issuance of restricted stock, net of cancellations	0	$ 3	(3)
Share-based compensation expense	4,730		4,730
Net loss	(8,479)			(8,479)
Other comprehensive income (loss)	(3,618)				(3,618)
Balance (in shares) at Jun. 29, 2019		50,771
Balance at Jun. 29, 2019	$ 590,966	$ 508	$ 525,038	$ 99,418	$ (33,998)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Jun. 29, 2019	Jun. 30, 2018
Cash Flows from Operating Activities:
Net loss	$ (8,479)	$ (2,819)
Non-cash items:
Depreciation and amortization	27,437	26,415
Impairment of assets	48,721	21,170
Share-based compensation expense	4,730	3,379
Deferred tax benefit	(5,309)	0
Provision for losses on accounts receivable and inventory	(1,378)	(352)
Other non-cash operating activities	50	19
Change in operating assets and liabilities:
Change in accounts receivable	22,518	(1,577)
Change in inventories	(37,414)	(15,058)
Change in prepaid income taxes	(3,228)	72
Change in other assets and other liabilities	(8,208)	(1,214)
Change in accounts payable and accrued expenses	(36,812)	(6,913)
Net cash provided by operating activities	2,628	23,122
Cash Flows from Investing Activities:
Capital expenditures	(8,249)	(27,514)
Proceeds from divestiture	9,808	0
Proceeds from sale of property, plant and equipment	302	250
Net cash provided by (used in) investing activities	1,861	(27,264)
Cash Flows from Financing Activities:
Net increase in short-term loans	90,000	0
Term loan borrowings	0	347,780
Repayment of term loan borrowings	(4,375)	(253,728)
Proceeds from employee stock purchase plan	1,830	1,780
Proceeds from exercise of stock options	3,635	2,831
Share repurchases	(75,000)	(80,000)
Net cash provided by financing activities	16,090	18,663
Effect of exchange rates on cash and cash equivalents	304	(2,584)
Net Change in Cash and Cash Equivalents	20,883	11,937
Cash and Cash Equivalents at Beginning of Period	169,351	180,169
Cash and Cash Equivalents at End of Period	190,234	192,106
Supplemental Disclosures of Cash Flow Information:
Interest paid	3,535	2,361
Income taxes paid	3,078	1,817
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 2,973	$ 1,799

BASIS OF PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Jun. 29, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	1. BASIS OF PRESENTATION Basis of Presentation The accompanying unaudited consolidated financial statements of Haemonetics Corporation ("Haemonetics" or the "Company") presented herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of the Company's management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. All intercompany transactions have been eliminated. Operating results for the three months ended June 29, 2019 are not necessarily indicative of the results that may be expected for the full fiscal year ending March 28, 2020 or any other interim period. The Company has assessed its ability to continue as a going concern. As of June 29, 2019 , the Company has concluded that substantial doubt about its ability to continue as a going concern does not exist. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the annual report on Form 10-K for the fiscal year ended March 30, 2019 . The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. There were no material recognized or unrecognized subsequent events as of and for the three months ended June 29, 2019 .

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	3 Months Ended
	Jun. 29, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	2. RECENT ACCOUNTING PRONOUNCEMENTS Standards Implemented In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Codification ("ASC") Update No. 2016-02, Leases (Topic 842) . ASC Update No. 2016-02 is intended to increase the transparency and comparability among organizations by recognizing lease asset and lease liabilities on the balance sheet, including those previously classified as operating leases under current U.S. GAAP and disclosing key information about leasing arrangements. In July 2018, the FASB issued an update to the leasing guidance to allow an additional transition option which would allow companies to adopt the standard as of the beginning of the year of adoption as opposed to the earliest comparative period presented. The Company adopted the new standard on March 31, 2019. Upon transition, the Company applied the package of practical expedients permitted under ASC Update No. 2016-02 transition guidance to its entire lease portfolio at March 31, 2019. As a result, the Company is not required to reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases, and (iii) initial direct costs for any existing leases. The Company also elected to account for each lease component and the associated non-lease components as a single lease component and also elected not to recognize a lease liability or right-of-use asset for any lease that, at commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. As a result of adopting ASC Update No. 2016-02, the Company recognized additional right-of-use assets of $22.9 million and corresponding liabilities of $22.7 million for its existing lease portfolio on the consolidated balance sheets, with no material impact to the consolidated statements of operations or consolidated statements of cash flows. Additionally, the Company implemented a new lease administration and lease accounting system and has updated controls and procedures for maintaining and accounting for its lease portfolio under the new standard. In March 2017, the FASB issued ASC Update No. 2017-07, Compensation - Retirement Benefits (Topic 715). The guidance revises the presentation of net periodic pension cost and net periodic post-retirement benefit cost. The Company adopted ASC Update No. 2017-07 during the first quarter of fiscal 2020. The adoption of ASC Update No. 2017-07 did not have a material impact on the Company's consolidated financial statements. In June 2018, the FASB issued ASC Update No. 2018-07, Compensation - Stock Compensation (Topic 718). The new guidance aligns the accounting for non-employee share-based payments with the existing employee share-based transactions guidance. The Company adopted ASC Update No. 2018-07 during the first quarter of fiscal 2020. The impact of adopting ASC Update No. 2018-07 did not have a material impact on the Company's financial position and results of operations.

RESTRUCTURING

RESTRUCTURING	3 Months Ended
	Jun. 29, 2019
Restructuring and Related Activities [Abstract]
RESTRUCTURING	3. RESTRUCTURING On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify opportunities for efficiencies, enhance commercial capabilities, align its resources and offer its customers better solutions. In order to realize these opportunities, the Company undertakes restructuring-type activities to transform its business. In July 2019, the Board of Directors of the Company approved a new Operational Excellence Program (the "2020 Program") and delegated authority to the Company's management to determine the detail of the initiatives that will comprise the program. The 2020 Program is designed to improve operational performance and reduce cost principally in our manufacturing and supply chain operations. The Company estimates that it will incur aggregate charges between $60 million and $70 million in connection with the 2020 Program. These charges, the majority of which will result in cash outlays, including severance and other employee costs, will be incurred as the specific actions required to execute these initiatives are identified and approved and are expected to be substantially completed by the end of fiscal 2023. Savings from the 2020 Program are targeted to reach $80 million to $90 million on an annualized basis once the program is completed. During fiscal 2018, the Company launched a Complexity Reduction Initiative (the "2018 Program"), a company-wide restructuring program designed to improve operational performance and reduce cost, freeing up resources to invest in accelerated growth. During the three months ended June 29, 2019 and June 30, 2018, the Company incurred $2.0 million and $3.4 million of restructuring and turnaround costs under this program, respectively. Total cumulative charges under this program are $52.3 million . The following table summarizes the activity for restructuring reserves for the three months ended June 29, 2019 , substantially all of which relates to employee severance and other employee costs: (In thousands) 2018 Program and Prior Programs Balance at March 30, 2019 $ 7,479 Costs incurred, net of reversals 969 Payments (3,206 ) Balance at June 29, 2019 $ 5,242 The substantial majority of restructuring costs during the three months ended June 29, 2019 have been included as a component of selling, general and administrative expenses in the accompanying consolidated statements of loss. As of June 29, 2019 , the Company had a restructuring liability of $5.2 million , of which $4.5 million is payable within the next twelve months. In addition to the restructuring costs included in the table above, during the three months ended June 29, 2019 and June 30, 2018, the Company also incurred costs of $1.1 million and $3.6 million , respectively, that do not constitute restructuring under ASC 420, Exit and Disposal Cost Obligations, which the Company refers to as turnaround costs. These costs, substantially all of which have been included as a component of selling, general and administrative expenses in the accompanying consolidated statements of loss, consist primarily of expenditures directly related to the restructuring actions and include program management costs associated with the implementation of outsourcing initiatives and recent accounting standards. The tables below present restructuring and turnaround costs by the Company's three reportable segments as well as the Company's other corporate restructuring and turnaround costs: Restructuring costs Three Months Ended (In thousands) June 29, 2019 June 30, 2018 Plasma $ 153 $ (39 ) Blood Center 42 (32 ) Hospital 203 6 Corporate 571 (227 ) Total $ 969 $ (292 ) Turnaround costs Three Months Ended (In thousands) June 29, 2019 June 30, 2018 Plasma $ 48 $ 12 Blood Center — — Hospital — (71 ) Corporate 1,010 3,700 Total $ 1,058 $ 3,641 Total restructuring and turnaround costs $ 2,027 $ 3,349

DIVESTITURE

DIVESTITURE	3 Months Ended
	Jun. 29, 2019
Discontinued Operations and Disposal Groups [Abstract]
DIVESTITURE	4. DIVESTITURE On May 21, 2019, the Company transferred to CSL Plasma Inc. (“CSL”) substantially all of its tangible assets held relating to the manufacture of anti-coagulant and saline (together, “Liquids”) at its Union, South Carolina facility (“Union”), which consist primarily of property, plant and equipment and inventory, and CSL assumed certain related liabilities (the “Asset Transfer”) pursuant to the terms of a settlement, release and asset transfer agreement between the parties dated May 13, 2019. The Asset Transfer excludes all other assets related to Union, including accounts receivable, customer contracts and the Company's U.S. Food and Drug Administration (“FDA”) product approvals for manufacturing Liquids. At closing, Haemonetics received $9.8 million of proceeds for the Asset Transfer and was concurrently released from its obligations to supply Liquids under a 2014 supply agreement with CSL. In connection with the Asset Transfer, CSL and Haemonetics also entered into related transition services, supply and manufacturing services and quality agreements that, among other things, permit CSL to manufacture Liquids under the Company's FDA product approvals, exclusively for Haemonetics and CSL, until CSL obtains independent product approvals from the FDA to manufacture the Liquids. The Company will continue to supply Liquids to its customers following the Asset Transfer pursuant to its supplier arrangements with contract manufacturers. In connection with the Company's and CSL's entry in to the May 13, 2019 agreement for the Asset Transfer, the Company recognized a pre-tax impairment charge of $48.7 million in the first quarter of fiscal 2020, primarily related to the carrying balances of the property, plant and equipment exceeding the consideration received under the terms of the Agreement. The charge will not result in any future cash expenditures.

INCOME TAXES

INCOME TAXES	3 Months Ended
	Jun. 29, 2019
Income Tax Disclosure [Abstract]
INCOME TAXES	5. INCOME TAXES The Company conducts business globally and reports its results of operations in a number of foreign jurisdictions in addition to the United States. The Company's reported tax rate is impacted by the jurisdictional mix of earnings in any given period as the foreign jurisdictions in which it operates have tax rates that differ from the U.S. statutory tax rate. The Company's reported tax rate for the three months ended June 29, 2019 was 52.2% . The effective tax rate for the three months ended June 29, 2019 is higher than the U.S. statutory tax rate primarily due to the jurisdictional mix of earnings, as well as the impact of the divestiture of the Union liquid solutions operation which resulted in a worldwide pretax loss for the quarter. The tax rate for the three months ended June 29, 2019 also includes a discrete stock compensation windfall benefit of $4.9 million . Refer to Note 4 , Divestiture for additional details related to the divestiture of the Union liquid solutions operation. During the three months ended June 29, 2019 and June 30, 2018 , the Company reported an income tax benefit of $9.2 million and expense of $6.1 million , respectively. The change in the Company's tax provision for the three months ended June 29, 2019 was primarily due to the divestiture of the plasma liquid solutions operation as well as an increase in stock compensation windfall benefits. The income tax provision for the three months ended June 30, 2018 was primarily attributable to applying the Company’s estimated annual effective tax rate to its year-to-date consolidated income before provision for income taxes, and includes a discrete tax benefit of $1.4 million

EARNINGS PER SHARE ("EPS")

EARNINGS PER SHARE ("EPS")	3 Months Ended
	Jun. 29, 2019
Earnings Per Share [Abstract]
EARNINGS PER SHARE (EPS)	6. EARNINGS PER SHARE (“EPS”) The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations. Three Months Ended (In thousands, except per share amounts) June 29, June 30, Basic EPS Net loss $ (8,479 ) $ (2,819 ) Weighted average shares 51,010 52,119 Basic loss per share $ (0.17 ) $ (0.05 ) Diluted EPS Net loss $ (8,479 ) $ (2,819 ) Basic weighted average shares 51,010 52,119 Net effect of common stock equivalents — — Diluted weighted average shares 51,010 52,119 Diluted loss per share $ (0.17 ) $ (0.05 ) Basic earnings per share is calculated using the Company's weighted-average outstanding common stock. Diluted earnings per share is calculated using its weighted-average outstanding common stock including the dilutive effect of stock awards as determined under the treasury stock method. For both the three months ended June 29, 2019 and June 30, 2018, the Company recognized a net loss; therefore it excluded the impact of outstanding stock awards from the diluted loss per share calculation as its inclusion would have an anti-dilutive effect. Share Repurchase Program In May 2019, the Company's Board of Directors authorized the repurchase of up to $500 million of Haemonetics common shares over the next two years. In early June 2019, the Company entered into an accelerated share repurchase agreement ("ASR") with Citibank N.A. ("Citibank") to repurchase approximately $75.0 million of the Company’s common stock. Pursuant to the terms of the ASR, in June 2019, the Company paid Citibank $75.0 million in cash and received an initial delivery of approximately 0.6 million shares of the Company's common stock based on a closing market price on the New York Stock Exchange on June 3, 2019 of $97.45 . This initial delivery of shares represented approximately 80% of the notional amount of the ASR. On July 30, 2019, the ASR was completed and an additional 29,018 shares were delivered upon settlement. The total number of shares repurchased under the ASR was approximately 0.6 million at an average price per share upon final settlement of $116.33 . As of August 6, 2019, the total remaining authorization for repurchases of the Company's common stock under the share repurchase program was $425 million .

REVENUE

REVENUE	3 Months Ended
	Jun. 29, 2019
Revenue from Contract with Customer [Abstract]
REVENUE	7. REVENUE The Company's revenue recognition policy is to recognize revenues from product sales, software and services in accordance with ASC Topic 606, Revenue from Contracts with Customers . Revenue is recognized when obligations under the terms of a contract with a customer are satisfied; this occurs with the transfer of control of the Company’s goods or services. The Company considers revenue to be earned when all of the following criteria are met: it has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the consideration it expects to receive for transferring goods or providing services, is determinable and it has transferred control of the promised items to the customer. A promise in a contract to transfer a distinct good or service to the customer is identified as a performance obligation. A contract’s transaction price is allocated to each performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Some of the Company’s contracts have multiple performance obligations. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation based on the estimated standalone selling prices of the good or service in the contract. For goods or services for which observable standalone selling prices are not available, the Company uses an expected cost plus a margin approach to estimate the standalone selling price of each performance obligation. As of June 29, 2019 , the Company had $24.9 million of its transaction price allocated to remaining performance obligations related to executed contracts with an original duration of one year or more. The Company expects to recognize approximately 58% of this amount as revenue within the next twelve months and the remaining balance thereafter. Contract Balances The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheets. The difference in timing between billing and revenue recognition primarily occurs in software licensing arrangements, resulting in contract assets and contract liabilities. As of June 29, 2019 and March 30, 2019 , the Company had contract assets of $8.3 million and $5.6 million , respectively. The change is primarily due to the delay in billings compared to the revenue recognized. Contract assets are classified as other current assets and other long-term assets on the consolidated balance sheet. As of June 29, 2019 and March 30, 2019 , the Company had contract liabilities of $21.9 million and $20.3 million , respectively. During the three months ended June 29, 2019 , the Company recognized $8.5 million of revenue that was included in the above March 30, 2019 contract liability balance. Contract liabilities are classified as other current liabilities and other long-term liabilities on the consolidated balance sheet.

INVENTORIES

INVENTORIES	3 Months Ended
	Jun. 29, 2019
Inventory Disclosure [Abstract]
INVENTORIES	8. INVENTORIES Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined using the first-in, first-out method. (In thousands) June 29, March 30, 2019 Raw materials $ 72,556 $ 69,420 Work-in-process 12,546 12,610 Finished goods 136,851 112,307 Total inventories $ 221,953 $ 194,337

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	3 Months Ended
	Jun. 29, 2019
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	9. PROPERTY, PLANT AND EQUIPMENT In December 2018, the Company entered into a lease for office space in Boston, MA that will serve as the new corporate headquarters and replace the existing location in Braintree, MA. During the first quarter of fiscal 2020, the Company entered into a purchase and sale agreement for the existing corporate headquarters. Accordingly, the Company reclassified $7.6 million of long-term assets associated with the current corporate headquarters to assets held-for-sale as of June 29, 2019. The Company expects the move to Boston will occur in the third quarter of fiscal 2020. During the first quarter of fiscal 2019, the Company recorded impairment charges of $21.2 million , which consisted of $19.8 million of charges related to the discontinued use of the HDC filter media manufacturing line and $1.4 million

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	3 Months Ended
	Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS	10. GOODWILL AND INTANGIBLE ASSETS Subsequent to the annual goodwill impairment test performed in the fourth quarter of fiscal 2019, the Company revised the composition of its reportable segments to align with its three global business units, Plasma, Blood Center and Hospital. Refer to Note 15 , Segment and Enterprise-Wide Information , for additional information regarding the change in the Company's reportable segments . A reporting unit is defined as an operating segment or one level below an operating segment, referred to as a component. The Company aggregates components within an operating segment that have similar economic characteristics. Consistent with its reportable segments, reporting units for purposes of assessing goodwill impairment have also been reorganized based on business unit and include: Plasma, Blood Center and Hospital. To determine the amount of goodwill within each of the new reporting units, we reallocated, on a relative fair value basis, $84.0 million of goodwill previously allocated to the former Europe, APAC and Japan reporting units to the new global reporting units. In addition, the goodwill previously allocated to the former North America reporting units was reallocated to each new respective global reporting unit. The following represents our goodwill balance by new global reportable segment. The prior period information has been restated to conform to the current presentation: (In thousands) Plasma Blood Center Hospital Total Carrying amount as of March 30, 2019 $ 28,828 $ 37,319 $ 144,672 $ 210,819 Currency translation — 66 255 321 Carrying amount as of June 29, 2019 $ 28,828 $ 37,385 $ 144,927 $ 211,140

LEASES

LEASES	3 Months Ended
	Jun. 29, 2019
Leases [Abstract]
LEASES	11. LEASES Lessee Activity The Company has operating leases for office space, land, warehouse and manufacturing space, R&D laboratories, vehicles and certain equipment. Finance leases are not significant. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of 1 year to approximately 30 years, some of which may include options to extend the leases for up to 10 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees. The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. For operating leases that commenced prior to the Company's adoption of ASC 842, the Company measured the lease liabilities and right-of-use assets using the incremental borrowing rate as of March 31, 2019. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. The following table presents supplemental balance sheet information related to the Company's operating leases: (In thousands) June 29, Assets Operating lease right-of-use assets in Other long-term assets $ 21,217 Liabilities Operating lease liabilities in Other current liabilities $ 5,554 Operating lease liabilities in Other long-term liabilities 15,293 The following table presents the weighted average remaining lease term and discount rate information related to our operating leases: June 29, Weighted average remaining lease term 4.8 Years Weighted average discount rate 5.19 % During the three months ended June 29, 2019 the Company's operating lease cost was $2.5 million . The following table presents supplemental cash flow information related to our operating leases: (In thousands) Three months ended June 29, 2019 Cash paid for amounts included in the measurement of operating lease liabilities Operating cash flows from operating leases $ 2,051 The following table presents the maturities of our operating lease liabilities as of June 29, 2019 : Fiscal Year ( in thousands ) Operating Leases 2020 (excluding the first quarter of 2020) $ 4,989 2021 5,828 2022 4,229 2023 3,288 2024 1,856 Thereafter 3,594 Total future minimum operating lease payments 23,784 Less: imputed interest (2,937 ) Present value of operating lease liabilities $ 20,847 As of June 29, 2019 , we have an additional lease for office space of $98.6 million . This lease will commence during fiscal 2020 and has a lease term, including renewal options, of up to 22 years . Lessor Activity Assets on the Company's balance sheet classified as Haemonetics equipment primarily consists of medical devices installed at customer sites but owned by Haemonetics. These devices are leased to customers under contractual arrangements that typically include and operating or sales-type lease as well as the purchase and consumption of a certain level of disposable products. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where devices are provided under operating lease arrangements, a substantial majority of the entire lease revenue is variable and subject to subsequent non-lease component (disposable products) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Operating lease revenue represents less than 3 percent of the Company's total net sales.

DEBT

DEBT	3 Months Ended
	Jun. 29, 2019
Debt Disclosure [Abstract]
NOTES PAYABLE AND LONG-TERM DEBT	12. NOTES PAYABLE AND LONG-TERM DEBT On June 15, 2018, the Company entered into a credit agreement with certain lenders which provided for a $350.0 million term loan (the "Term Loan") and a $350.0 million revolving loan (the "Revolving Credit Facility" and together with the Term Loan, the "Credit Facilities"). The Credit Facilities expire on June 15, 2023. Interest on the Credit Facilities is established using LIBOR plus 1.13% - 1.75% , depending on the Company's leverage ratio. Under the Credit Facilities, the Company is required to maintain certain leverage and interest coverage ratios specified in the credit agreement as well as other customary non-financial affirmative and negative covenants. At June 29, 2019 , $332.5 million was outstanding under the Term Loan with an effective interest rate of 3.8% and $105.0 million was outstanding on the Revolving Credit Facility. The Company also has $25.8 million of uncommitted operating lines of credit to fund its global operations under which there were no outstanding borrowings as of June 29, 2019 . The Company has required scheduled principal payments of $8.8 million during fiscal 2020, $21.9 million during fiscal 2021, $17.5 million during fiscal 2022, $214.4 million during fiscal 2023 and $70.0 million thereafter. The Company was in compliance with the leverage and interest coverage ratios specified in the Credit Facilities as well as all other bank covenants as of June 29, 2019 .

DERIVATIVES AND FAIR VALUE MEAS

DERIVATIVES AND FAIR VALUE MEASUREMENTS	3 Months Ended
	Jun. 29, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVES AND FAIR VALUE MEASUREMENTS	13. DERIVATIVES AND FAIR VALUE MEASUREMENTS The Company manufactures, markets and sells its products globally. During the three months ended June 29, 2019 , 34.4% of its sales were generated outside the U.S., generally in foreign currencies. The Company also incurs certain manufacturing, marketing and selling costs in international markets in local currency. Accordingly, earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the U.S. Dollar, the Company's reporting currency. The Company has a program in place that is designed to mitigate the exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize, for a period of time, the impact on its financial results from changes in foreign exchange rates. The Company utilizes foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily the Japanese Yen and the Euro, and to a lesser extent the Swiss Franc, Australian Dollar, Canadian Dollar and the Mexican Peso. This does not eliminate the impact of the volatility of foreign exchange rates. However, because the Company generally enters into forward contracts one year out, rates are fixed for a one -year period, thereby facilitating financial planning and resource allocation. Designated Foreign Currency Hedge Contracts All of the Company's designated foreign currency hedge contracts as of June 29, 2019 and March 30, 2019 were cash flow hedges under ASC 815, Derivatives and Hedging ("ASC 815"). The Company records the effective portion of any change in the fair value of designated foreign currency hedge contracts in other comprehensive income until the related third-party transaction occurs. Once the related third-party transaction occurs, the Company reclassifies the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, the Company would reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. The Company had designated foreign currency hedge contracts outstanding in the contract amount of $66.4 million as of June 29, 2019 and $81.5 million as of March 30, 2019 . At June 29, 2019 , gain of $0.7 million , net of tax, will be reclassified to earnings within the next twelve months . Substantially all currency cash flow hedges outstanding as of June 29, 2019 mature within twelve months . Non-Designated Foreign Currency Contracts The Company manages its exposure to changes in foreign currency on a consolidated basis to take advantage of offsetting transactions and balances. It uses foreign currency forward contracts as a part of its strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month. They are not designated as cash flow or fair value hedges under ASC 815. These forward contracts are marked-to-market with changes in fair value recorded to earnings. The Company had non-designated foreign currency hedge contracts under ASC 815 outstanding in the contract amount of $82.1 million as of June 29, 2019 and $37.4 million as of March 30, 2019 . Interest Rate Swaps On June 15, 2018, the Company entered into Credit Facilities which provided for a $350.0 million Term Loan and a $350.0 million Revolving Credit Facility. Under the terms of the Credit Facilities, interest is established using LIBOR plus 1.13% - 1.75% . As a result, the Company's earnings and cash flows are exposed to interest rate risk from changes to LIBOR. Part of the Company's interest rate risk management strategy includes the use of interest rate swaps to mitigate its exposure to changes in variable interest rates. The Company's objective in using interest rate swaps is to add stability to interest expense and to manage and reduce the risk inherent in interest rate fluctuations. In August 2018, the Company entered into two interest rate swap agreements (the "Swaps") to pay an average fixed rate of 2.80% on a total notional value of $241.9 million of debt. As a result of the interest rate swaps, 70% of the Term Loan exposed to interest rate risk from changes in LIBOR are fixed at a rate of 4.05% . The Swaps mature on June 15, 2023. The Company designated the Swaps as cash flow hedges of variable interest rate risk associated with $332.5 million of indebtedness. For the three months ended June 29, 2019 , a loss of $4.3 million , net of tax, was recorded in accumulated other comprehensive loss to recognize the effective portion of the fair value of the Swaps that qualify as cash flow hedges. Fair Value of Derivative Instruments The following table presents the effect of the Company's derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC 815 in its consolidated statements of loss and comprehensive loss for the three months ended June 29, 2019 : (In thousands) Amount of Gain Amount of Gain (Loss) Reclassified Location in Amount of Gain Excluded from Testing Location in Designated foreign currency hedge contracts, net of tax $ 672 $ 336 Net revenues, COGS and SG&A $ 199 Interest and other expense, net Non-designated foreign currency hedge contracts — — $ (256 ) Interest and other expense, net Designated interest rate swaps, net of tax $ (4,292 ) $ (143 ) Interest and other expense, net $ — The Company did not have fair value hedges or net investment hedges outstanding as of June 29, 2019 or March 30, 2019 . As of June 29, 2019 , no deferred tax assets were recognized for designated foreign currency hedges. ASC 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. The Company determines the fair value of its derivative instruments using the framework prescribed by ASC 820, Fair Value Measurements and Disclosures , by considering the estimated amount it would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets, and its creditworthiness for liabilities. In certain instances, the Company may utilize financial models to measure fair value. Generally, it uses inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of June 29, 2019 , the Company has classified its derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC 815, as discussed below, because these observable inputs are available for substantially the full term of its derivative instruments. The following tables present the fair value of the Company's derivative instruments as they appear in its consolidated balance sheets as of June 29, 2019 and March 30, 2019 : (In thousands) Location in As of As of June 29, 2019 March 30, 2019 Derivative Assets: Designated foreign currency hedge contracts Other current assets $ 550 $ 1,208 Non-designated foreign currency hedge contracts Other current assets 41 69 $ 591 $ 1,277 Derivative Liabilities: Designated foreign currency hedge contracts Other current liabilities $ 585 $ 145 Non-designated foreign currency hedge contracts Other current liabilities 436 — Designated interest rate swaps Other current liabilities 9,071 5,203 $ 10,092 $ 5,348 Other Fair Value Measurements Fair value is defined as the exit price that would be received from the sale of an asset or paid to transfer a liability, using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes the following three-level hierarchy used for measuring fair value: • Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities. • Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs. • Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk. The Company's money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. Fair Value Measured on a Recurring Basis Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of June 29, 2019 and March 30, 2019 . As of June 29, 2019 (In thousands) Level 1 Level 2 Total Assets Money market funds $ 35,506 $ — $ 35,506 Designated foreign currency hedge contracts — 550 550 Non-designated foreign currency hedge contracts — 41 41 $ 35,506 $ 591 $ 36,097 Liabilities Designated foreign currency hedge contracts $ — $ 585 $ 585 Non-designated foreign currency hedge contracts — 436 436 Designated interest rate swaps — 9,071 9,071 $ — $ 10,092 $ 10,092 As of March 30, 2019 Level 1 Level 2 Total Assets Money market funds $ 36,980 $ — $ 36,980 Designated foreign currency hedge contracts — 1,208 1,208 Non-designated foreign currency hedge contracts — 69 69 $ 36,980 $ 1,277 $ 38,257 Liabilities Designated foreign currency hedge contracts $ — $ 145 $ 145 Designated interest rate swaps $ — $ 5,203 $ 5,203 $ — $ 5,348 $ 5,348 Other Fair Value Disclosures The Term Loan, which is carried at amortized cost, accounts receivable and accounts payable approximate fair value.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Jun. 29, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	14. COMMITMENTS AND CONTINGENCIES The Company is a party to various legal proceedings and claims arising out of the ordinary course of its business. The Company believes that except for those matters described below, there are no other proceedings or claims pending against it the ultimate resolution of which could have a material adverse effect on the financial condition or results of operations. At each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies, for all matters. Legal costs are expensed as incurred. Litigation and Related Matters Product Recall In August 2018, the Company issued a voluntary recall of certain whole blood collection kits sold to its Blood Center customers in the U.S. The recall resulted from some collection sets' filters failing to adequately remove leukocytes from collected blood. As a result of the recall, the Company's Blood Center customers may have conducted tests to confirm that the collected blood was adequately leukoreduced, sold the collected blood labeled as non-leukoreduced at a lower price or discarded the collected blood. As of June 29, 2019 , the Company has recorded cumulative charges of $1.9 million associated with this recall which consists of $0.1 million of charges associated with customer returns and inventory reserves and $1.8 million of charges associated with customer claims. Substantially all outstanding claims have been paid as of June 29, 2019 .

SEGMENT AND ENTERPRISE-WIDE INF

SEGMENT AND ENTERPRISE-WIDE INFORMATION	3 Months Ended
	Jun. 29, 2019
Segment Reporting [Abstract]
SEGMENT AND ENTERPRISE-WIDE INFORMATION	15. SEGMENT AND ENTERPRISE-WIDE INFORMATION The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. Historically, the Company's operating segments were based primarily on geography. Effective as of March 31, 2019, the Company completed the transition of its operating structuring to three global business units and accordingly has reorganized its reporting structure to align with its three global business units and the information that will be regularly reviewed by the Company's chief operating decision maker. Following the reorganization, the Company's reportable segments are as follows: • Plasma • Blood Center • Hospital Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include restructuring and turnaround costs, deal amortization, asset impairments, accelerated depreciation, certain transaction costs and legal charges. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company's net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis. Selected information by reportable segment is presented below: Three Months Ended (In thousands) June 29, June 30, Net revenues Plasma $ 110,763 $ 99,290 Blood Center 77,996 79,818 Hospital 47,187 45,845 Net revenues by business unit 235,946 224,953 Service (1) 4,866 4,325 Effect of exchange rates (2,361 ) 69 Net revenues $ 238,451 $ 229,347 (1) Reflects revenue for service, maintenance and parts Three Months Ended (In thousands) June 29, June 30, Segment operating income Plasma $ 53,725 $ 41,921 Blood Center 37,719 38,472 Hospital 18,916 18,328 Segment operating income 110,360 98,721 Corporate expenses (1) (61,703 ) (61,050 ) Effect of exchange rates 2,769 3,055 Impairment of assets and other related charges (51,166 ) (21,170 ) Deal amortization (5,974 ) (6,300 ) PCS2 accelerated depreciation and related costs (5,528 ) (3,939 ) Restructuring and turnaround costs (2,027 ) (3,349 ) Other (33 ) (675 ) Operating (loss) income $ (13,302 ) $ 5,293 (1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions. (In thousands) June 29, March 30, Long-lived assets (1) Plasma $ 168,816 $ 209,827 Blood Center 88,560 110,073 Hospital 19,372 24,079 Total long-lived assets $ 276,748 $ 343,979 (1) Long-lived assets are comprised of property, plant and equipment. Management reviews revenue based on the reportable segments noted above. Although these reportable segments are primarily product-based, they differ from the Company’s product line revenues for Plasma products and services and Blood Center products and services. Specifically, the Blood Center reportable segment includes plasma products utilized for collection in blood centers primarily for transfusion purposes. Additionally, product line revenues also include service revenues which are excluded from the reportable segments. Net revenues by product line are as follows: Three Months Ended (In thousands) June 29, June 30, Plasma products and services $ 129,745 $ 116,903 Blood Center products and services 59,907 64,483 Hospital products and services 48,799 47,961 Net revenues $ 238,451 $ 229,347 Net revenues generated in the Company's principle operating regions on a reported basis are as follows: Three Months Ended (In thousands) June 29, June 30, United States $ 156,375 $ 142,140 Japan 15,467 17,389 Europe 36,753 39,002 Asia 28,641 29,395 Other 1,215 1,421 Net revenues $ 238,451 $ 229,347

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE LOSS	3 Months Ended
	Jun. 29, 2019
Stockholders' Equity Note [Abstract]
ACCUMULATED OTHER COMPREHENSIVE LOSS	16. ACCUMULATED OTHER COMPREHENSIVE LOSS The components of Accumulated Other Comprehensive Loss are as follows: (In thousands) Foreign Currency Defined Benefit Plans Net Unrealized Gain/Loss on Derivatives Total Balance as of March 30, 2019 $ (25,513 ) $ (527 ) $ (4,340 ) $ (30,380 ) Other comprehensive loss before reclassifications (1) 195 — (3,620 ) (3,425 ) Amounts reclassified from Accumulated Other Comprehensive Loss (1) — — (193 ) (193 ) Net current period other comprehensive income (loss) 195 — (3,813 ) (3,618 ) Balance as of June 29, 2019 $ (25,318 ) $ (527 ) $ (8,153 ) $ (33,998 ) (1) Presented net of income taxes, the amounts of which are insignificant.

RESTRUCTURING (Tables)

RESTRUCTURING (Tables)	3 Months Ended
	Jun. 29, 2019
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve by Type of Cost	The following table summarizes the activity for restructuring reserves for the three months ended June 29, 2019 , substantially all of which relates to employee severance and other employee costs: (In thousands) 2018 Program and Prior Programs Balance at March 30, 2019 $ 7,479 Costs incurred, net of reversals 969 Payments (3,206 ) Balance at June 29, 2019 $ 5,242
Schedule of Restructuring and Related Costs	The tables below present restructuring and turnaround costs by the Company's three reportable segments as well as the Company's other corporate restructuring and turnaround costs: Restructuring costs Three Months Ended (In thousands) June 29, 2019 June 30, 2018 Plasma $ 153 $ (39 ) Blood Center 42 (32 ) Hospital 203 6 Corporate 571 (227 ) Total $ 969 $ (292 ) Turnaround costs Three Months Ended (In thousands) June 29, 2019 June 30, 2018 Plasma $ 48 $ 12 Blood Center — — Hospital — (71 ) Corporate 1,010 3,700 Total $ 1,058 $ 3,641 Total restructuring and turnaround costs $ 2,027 $ 3,349

EARNINGS PER SHARE ("EPS") (Tab

EARNINGS PER SHARE ("EPS") (Tables)	3 Months Ended
	Jun. 29, 2019
Earnings Per Share [Abstract]
Schedule of Earnings Per Share Reconciliation	The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations. Three Months Ended (In thousands, except per share amounts) June 29, June 30, Basic EPS Net loss $ (8,479 ) $ (2,819 ) Weighted average shares 51,010 52,119 Basic loss per share $ (0.17 ) $ (0.05 ) Diluted EPS Net loss $ (8,479 ) $ (2,819 ) Basic weighted average shares 51,010 52,119 Net effect of common stock equivalents — — Diluted weighted average shares 51,010 52,119 Diluted loss per share $ (0.17 ) $ (0.05 )

INVENTORIES (Tables)

INVENTORIES (Tables)	3 Months Ended
	Jun. 29, 2019
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined using the first-in, first-out method. (In thousands) June 29, March 30, 2019 Raw materials $ 72,556 $ 69,420 Work-in-process 12,546 12,610 Finished goods 136,851 112,307 Total inventories $ 221,953 $ 194,337

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	3 Months Ended
	Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following represents our goodwill balance by new global reportable segment. The prior period information has been restated to conform to the current presentation: (In thousands) Plasma Blood Center Hospital Total Carrying amount as of March 30, 2019 $ 28,828 $ 37,319 $ 144,672 $ 210,819 Currency translation — 66 255 321 Carrying amount as of June 29, 2019 $ 28,828 $ 37,385 $ 144,927 $ 211,140

LEASES (Tables)

LEASES (Tables)	3 Months Ended
	Jun. 29, 2019
Leases [Abstract]
Operating lease assets and liabilities	The following table presents supplemental balance sheet information related to the Company's operating leases: (In thousands) June 29, Assets Operating lease right-of-use assets in Other long-term assets $ 21,217 Liabilities Operating lease liabilities in Other current liabilities $ 5,554 Operating lease liabilities in Other long-term liabilities 15,293
Other lease information	The following table presents the weighted average remaining lease term and discount rate information related to our operating leases: June 29, Weighted average remaining lease term 4.8 Years Weighted average discount rate 5.19 %
Lease cost components	The following table presents supplemental cash flow information related to our operating leases: (In thousands) Three months ended June 29, 2019 Cash paid for amounts included in the measurement of operating lease liabilities Operating cash flows from operating leases $ 2,051
Operating lease liability maturity	The following table presents the maturities of our operating lease liabilities as of June 29, 2019 : Fiscal Year ( in thousands ) Operating Leases 2020 (excluding the first quarter of 2020) $ 4,989 2021 5,828 2022 4,229 2023 3,288 2024 1,856 Thereafter 3,594 Total future minimum operating lease payments 23,784 Less: imputed interest (2,937 ) Present value of operating lease liabilities $ 20,847

DERIVATIVES AND FAIR VALUE ME_2

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Jun. 29, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments	The following table presents the effect of the Company's derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC 815 in its consolidated statements of loss and comprehensive loss for the three months ended June 29, 2019 : (In thousands) Amount of Gain Amount of Gain (Loss) Reclassified Location in Amount of Gain Excluded from Testing Location in Designated foreign currency hedge contracts, net of tax $ 672 $ 336 Net revenues, COGS and SG&A $ 199 Interest and other expense, net Non-designated foreign currency hedge contracts — — $ (256 ) Interest and other expense, net Designated interest rate swaps, net of tax $ (4,292 ) $ (143 ) Interest and other expense, net $ —
Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets	The following tables present the fair value of the Company's derivative instruments as they appear in its consolidated balance sheets as of June 29, 2019 and March 30, 2019 : (In thousands) Location in As of As of June 29, 2019 March 30, 2019 Derivative Assets: Designated foreign currency hedge contracts Other current assets $ 550 $ 1,208 Non-designated foreign currency hedge contracts Other current assets 41 69 $ 591 $ 1,277 Derivative Liabilities: Designated foreign currency hedge contracts Other current liabilities $ 585 $ 145 Non-designated foreign currency hedge contracts Other current liabilities 436 — Designated interest rate swaps Other current liabilities 9,071 5,203 $ 10,092 $ 5,348
Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis	Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of June 29, 2019 and March 30, 2019 . As of June 29, 2019 (In thousands) Level 1 Level 2 Total Assets Money market funds $ 35,506 $ — $ 35,506 Designated foreign currency hedge contracts — 550 550 Non-designated foreign currency hedge contracts — 41 41 $ 35,506 $ 591 $ 36,097 Liabilities Designated foreign currency hedge contracts $ — $ 585 $ 585 Non-designated foreign currency hedge contracts — 436 436 Designated interest rate swaps — 9,071 9,071 $ — $ 10,092 $ 10,092 As of March 30, 2019 Level 1 Level 2 Total Assets Money market funds $ 36,980 $ — $ 36,980 Designated foreign currency hedge contracts — 1,208 1,208 Non-designated foreign currency hedge contracts — 69 69 $ 36,980 $ 1,277 $ 38,257 Liabilities Designated foreign currency hedge contracts $ — $ 145 $ 145 Designated interest rate swaps $ — $ 5,203 $ 5,203 $ — $ 5,348 $ 5,348

SEGMENT AND ENTERPRISE-WIDE I_2

SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables)	3 Months Ended
	Jun. 29, 2019
Segment Reporting [Abstract]
Selected Information by Business Segment	Selected information by reportable segment is presented below: Three Months Ended (In thousands) June 29, June 30, Net revenues Plasma $ 110,763 $ 99,290 Blood Center 77,996 79,818 Hospital 47,187 45,845 Net revenues by business unit 235,946 224,953 Service (1) 4,866 4,325 Effect of exchange rates (2,361 ) 69 Net revenues $ 238,451 $ 229,347 (1) Reflects revenue for service, maintenance and parts Three Months Ended (In thousands) June 29, June 30, Segment operating income Plasma $ 53,725 $ 41,921 Blood Center 37,719 38,472 Hospital 18,916 18,328 Segment operating income 110,360 98,721 Corporate expenses (1) (61,703 ) (61,050 ) Effect of exchange rates 2,769 3,055 Impairment of assets and other related charges (51,166 ) (21,170 ) Deal amortization (5,974 ) (6,300 ) PCS2 accelerated depreciation and related costs (5,528 ) (3,939 ) Restructuring and turnaround costs (2,027 ) (3,349 ) Other (33 ) (675 ) Operating (loss) income $ (13,302 ) $ 5,293 (1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.
Schedule of Revenues by Product Line and Geographic Regions	(In thousands) June 29, March 30, Long-lived assets (1) Plasma $ 168,816 $ 209,827 Blood Center 88,560 110,073 Hospital 19,372 24,079 Total long-lived assets $ 276,748 $ 343,979 (1) Long-lived assets are comprised of property, plant and equipment. Management reviews revenue based on the reportable segments noted above. Although these reportable segments are primarily product-based, they differ from the Company’s product line revenues for Plasma products and services and Blood Center products and services. Specifically, the Blood Center reportable segment includes plasma products utilized for collection in blood centers primarily for transfusion purposes. Additionally, product line revenues also include service revenues which are excluded from the reportable segments. Net revenues by product line are as follows: Three Months Ended (In thousands) June 29, June 30, Plasma products and services $ 129,745 $ 116,903 Blood Center products and services 59,907 64,483 Hospital products and services 48,799 47,961 Net revenues $ 238,451 $ 229,347 Net revenues generated in the Company's principle operating regions on a reported basis are as follows: Three Months Ended (In thousands) June 29, June 30, United States $ 156,375 $ 142,140 Japan 15,467 17,389 Europe 36,753 39,002 Asia 28,641 29,395 Other 1,215 1,421 Net revenues $ 238,451 $ 229,347

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)	3 Months Ended
	Jun. 29, 2019
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The components of Accumulated Other Comprehensive Loss are as follows: (In thousands) Foreign Currency Defined Benefit Plans Net Unrealized Gain/Loss on Derivatives Total Balance as of March 30, 2019 $ (25,513 ) $ (527 ) $ (4,340 ) $ (30,380 ) Other comprehensive loss before reclassifications (1) 195 — (3,620 ) (3,425 ) Amounts reclassified from Accumulated Other Comprehensive Loss (1) — — (193 ) (193 ) Net current period other comprehensive income (loss) 195 — (3,813 ) (3,618 ) Balance as of June 29, 2019 $ (25,318 ) $ (527 ) $ (8,153 ) $ (33,998 ) (1) Presented net of income taxes, the amounts of which are insignificant.

RECENT ACCOUNTING PRONOUNCEME_2

RECENT ACCOUNTING PRONOUNCEMENTS (Narrative) (Details) - USD ($) $ in Thousands	Jun. 29, 2019	Mar. 31, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease right-of-use assets in Other long-term assets	$ 21,217
Operating lease liability	$ 20,847
ASU 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease right-of-use assets in Other long-term assets		$ 22,900
Operating lease liability		$ 22,700

RESTRUCTURING (Narrative) (Deta

RESTRUCTURING (Narrative) (Details) $ in Thousands	3 Months Ended		27 Months Ended
	Jun. 29, 2019USD ($)segment	Jun. 30, 2018USD ($)	Jun. 29, 2019USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring and turnaround costs	$ 2,027	$ 3,349
Restructuring liability	$ 5,200		$ 5,200
Number of reportable segments | segment	3
Restructuring liability payable in next twelve months	$ 4,500		4,500
Restructuring costs	969	(292)
Turnaround costs	1,058	3,641
Selling, General and Administrative Expenses
Restructuring Cost and Reserve [Line Items]
Turnaround costs	1,100	3,600
2020 Program | Minimum
Restructuring Cost and Reserve [Line Items]
Expected cost	60,000		60,000
Expected savings	80,000		80,000
2020 Program | Maximum
Restructuring Cost and Reserve [Line Items]
Expected cost	70,000		70,000
Expected savings	90,000		90,000
2018 Program
Restructuring Cost and Reserve [Line Items]
Restructuring and turnaround costs	$ 2,000	$ 3,400	$ 52,300

RESTRUCTURING (Schedule of Rest

RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 29, 2019	Jun. 30, 2018
Restructuring Reserve [Roll Forward]
Costs incurred, net of reversals	$ 969	$ (292)
Balance at June 29, 2019	5,200
2018 Program and Prior Programs
Restructuring Reserve [Roll Forward]
Balance at March 30, 2019	7,479
Costs incurred, net of reversals	969
Payments	(3,206)
Balance at June 29, 2019	$ 5,242

RESTRUCTURING (Schedule of Re_2

RESTRUCTURING (Schedule of Restructuring and Related Costs) (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 29, 2019	Jun. 30, 2018
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 969	$ (292)
Turnaround costs	1,058	3,641
Total restructuring and turnaround costs	2,027	3,349
Blood Center
Restructuring Cost and Reserve [Line Items]
Restructuring costs	42	(32)
Turnaround costs	0	0
Hospital
Restructuring Cost and Reserve [Line Items]
Restructuring costs	203	6
Turnaround costs	0	(71)
Plasma
Restructuring Cost and Reserve [Line Items]
Restructuring costs	153	(39)
Turnaround costs	48	12
Corporate
Restructuring Cost and Reserve [Line Items]
Restructuring costs	571	(227)
Turnaround costs	$ 1,010	$ 3,700

DIVESTITURE (Details)

DIVESTITURE (Details) - USD ($) $ in Thousands	May 21, 2019	Jun. 29, 2019	Jun. 30, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture		$ 9,808	$ 0
Impairment of assets		48,721	$ 21,170
CSL Plasma Inc. | Disposal Group, Disposed of by Sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture	$ 9,800
Impairment of assets		$ 48,700

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 29, 2019	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Reported tax rate	52.20%
Discrete tax benefit	$ 4,900	$ 1,400
Provision (benefit) for income taxes	$ (9,246)	$ 6,134

EARNINGS PER SHARE ("EPS") (Sch

EARNINGS PER SHARE ("EPS") (Schedule of Earnings Per Share Reconciliation) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Jun. 29, 2019	Jun. 30, 2018
Basic EPS
Net loss	$ (8,479)	$ (2,819)
Basic and diluted (in shares)	51,010	52,119
Basic income (loss) per share (in dollars per share)	$ (0.17)	$ (0.05)
Diluted EPS
Net loss	$ (8,479)	$ (2,819)
Net effect of common stock equivalents (in shares)	0	0
Diluted weighted average shares (in shares)	51,010	52,119
Diluted income (loss) per share (in dollars per share)	$ (0.17)	$ (0.05)

EARNINGS PER SHARE ("EPS") (Sha

EARNINGS PER SHARE ("EPS") (Share Repurchase Program) (Details) - USD ($)	3 Months Ended
	Jun. 29, 2019	Jun. 30, 2018	Aug. 06, 2019	May 31, 2019
Accelerated Share Repurchases [Line Items]
Shares repurchased	$ 75,000,000	$ 80,000,000
ASR with Citibank
Accelerated Share Repurchases [Line Items]
Share repurchase plan, authorized amount	75,000,000
Shares repurchased	$ 75,000,000
Shares repurchased (in shares)	600,000
Share repurchase, notional amount	80.00%
Repurchase price (in dollars per share)	$ 97.45
Share Repurchase Program
Accelerated Share Repurchases [Line Items]
Shares repurchased (in shares)	29,018
Repurchase price (in dollars per share)	$ 116.33
Subsequent Event
Accelerated Share Repurchases [Line Items]
Remaining authorized amount			$ 425,000,000
Share Repurchase Program
Accelerated Share Repurchases [Line Items]
Share repurchase plan, authorized amount				$ 500,000,000

REVENUE (Details)

REVENUE (Details) - USD ($) $ in Millions	3 Months Ended
	Jun. 29, 2019	Mar. 30, 2019
Revenue from Contract with Customer [Abstract]
Performance obligation amount	$ 24.9
Performance obligation percent	58.00%
Expected timing of satisfaction	12 months
Contract assets	$ 8.3	$ 5.6
Contract liabilities	21.9	$ 20.3
Revenue recognized	$ 8.5

INVENTORIES (Schedule of Invent

INVENTORIES (Schedule of Inventories) (Details) - USD ($) $ in Thousands	Jun. 29, 2019	Mar. 30, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 72,556	$ 69,420
Work-in-process	12,546	12,610
Finished goods	136,851	112,307
Inventories, net	$ 221,953	$ 194,337

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Details) $ in Millions	3 Months Ended
	Jun. 29, 2019USD ($)
Property, Plant and Equipment [Line Items]
Increase in assets held-for-sale	$ 7.6
Impairment charges	21.2
HDC Line
Property, Plant and Equipment [Line Items]
Impairment charges	19.8
Non-core and Underperforming Assets
Property, Plant and Equipment [Line Items]
Impairment charges	$ 1.4

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS Schedule of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 29, 2019	Jun. 30, 2018
Goodwill [Roll Forward]
Goodwill, carrying amount	$ 210,819
Transfer of goodwill between segments		$ 84,000
Currency translation	321
Goodwill, carrying amount	211,140
Plasma
Goodwill [Roll Forward]
Goodwill, carrying amount	28,828
Currency translation	0
Goodwill, carrying amount	28,828
Blood Center
Goodwill [Roll Forward]
Goodwill, carrying amount	37,319
Currency translation	66
Goodwill, carrying amount	37,385
Hospital
Goodwill [Roll Forward]
Goodwill, carrying amount	144,672
Currency translation	255
Goodwill, carrying amount	$ 144,927

LEASES (Details)

LEASES (Details) $ in Thousands	3 Months Ended
	Jun. 29, 2019USD ($)
Lessee, Lease, Description [Line Items]
Renewal term	10 years
Operating lease right-of-use assets in Other long-term assets	$ 21,217
Operating lease liabilities in Other current liabilities	5,554
Operating lease liabilities in Other long-term liabilities	$ 15,293
Weighted-average remaining lease term (years)	4 years 9 months 18 days
Weighted-average discount rate	5.19%
Operating lease cost	$ 2,500
Operating cash flows from operating leases	2,051
2020	4,989
2021	5,828
2022	4,229
2023	3,288
2024	1,856
Thereafter	3,594
Total future minimum operating lease payments	23,784
Less: imputed interest	(2,937)
Present value of operating lease liabilities	$ 20,847
Minimum
Lessee, Lease, Description [Line Items]
Lease term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Lease term	30 years
Office Space
Lessee, Lease, Description [Line Items]
Lease term	22 years
Present value of operating lease liabilities	$ 98,600
Operating lease revenue
Lessee, Lease, Description [Line Items]
Concentration risk	3.00%

DEBT (Details)

DEBT (Details) - USD ($)	Jun. 15, 2018	Jun. 29, 2019
Credit Facilities
Debt Instrument [Line Items]
Principal repayments, fiscal 2020		$ 8,800,000
Principal repayments, fiscal 2021		21,900,000
Principal repayments, fiscal 2022		17,500,000
Principal repayments, fiscal 2023		214,400,000
Principal repayments, thereafter		70,000,000
Term Loan
Debt Instrument [Line Items]
Face amount of debt	$ 350,000,000
Debt outstanding		$ 332,500,000
Effective interest rate		3.80%
Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 350,000,000
Debt outstanding		$ 105,000,000
Revolving Credit Facility | LIBOR | Minimum
Debt Instrument [Line Items]
Interest rate	1.13%
Revolving Credit Facility | LIBOR | Maximum
Debt Instrument [Line Items]
Interest rate	1.75%
Uncommitted Operating Lines of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity		25,800,000
Debt outstanding		$ 0

DERIVATIVES AND FAIR VALUE ME_3

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details) $ in Thousands	3 Months Ended
	Jun. 29, 2019USD ($)
Designated as Hedging Instrument | Cash Flow Hedging | Net revenues, COGS and SG&A
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Accumulated Other Comprehensive Loss	$ 672
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Earnings	336
Designated as Hedging Instrument | Cash Flow Hedging | Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain Excluded from Effectiveness Testing	199
Designated as Hedging Instrument | Interest Rate Swap
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain Excluded from Effectiveness Testing	0
Designated as Hedging Instrument | Interest Rate Swap | Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Accumulated Other Comprehensive Loss	(4,292)
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Earnings	(143)
Not Designated as Hedging Instrument | Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Accumulated Other Comprehensive Loss	0
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Earnings	0
Not Designated as Hedging Instrument | Foreign Exchange Contract | Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain Excluded from Effectiveness Testing	$ (256)

DERIVATIVES AND FAIR VALUE ME_4

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedules of Derivatives) (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Jun. 29, 2019	Mar. 30, 2019
Assets
Money market funds	$ 35,506	$ 36,980
Assets fair value	36,097	38,257
Liabilities
Liabilities fair value	10,092	5,348
Level 1
Assets
Money market funds	35,506	36,980
Assets fair value	35,506	36,980
Liabilities
Liabilities fair value	0	0
Level 2
Assets
Money market funds	0	0
Assets fair value	591	1,277
Liabilities
Liabilities fair value	10,092	5,348
Designated as Hedging Instrument
Assets
Derivative Assets	591	1,277
Liabilities
Derivative Liabilities	10,092	5,348
Foreign Exchange Contract | Designated as Hedging Instrument
Assets
Derivative Assets	550	1,208
Liabilities
Derivative Liabilities	585	145
Foreign Exchange Contract | Designated as Hedging Instrument | Level 1
Assets
Derivative Assets	0	0
Liabilities
Derivative Liabilities	0	0
Foreign Exchange Contract | Designated as Hedging Instrument | Level 2
Assets
Derivative Assets		1,208
Liabilities
Derivative Liabilities		145
Foreign Exchange Contract | Not Designated as Hedging Instrument
Assets
Derivative Assets	41	69
Liabilities
Derivative Liabilities	436
Foreign Exchange Contract | Not Designated as Hedging Instrument | Level 1
Assets
Derivative Assets	0	0
Liabilities
Derivative Liabilities	0
Foreign Exchange Contract | Not Designated as Hedging Instrument | Level 2
Assets
Derivative Assets		69
Foreign Exchange Contract | Other Current Assets | Designated as Hedging Instrument
Assets
Derivative Assets		1,208
Foreign Exchange Contract | Other Current Assets | Designated as Hedging Instrument | Level 2
Assets
Derivative Assets	550
Foreign Exchange Contract | Other Current Assets | Not Designated as Hedging Instrument
Assets
Derivative Assets		69
Foreign Exchange Contract | Other Current Assets | Not Designated as Hedging Instrument | Level 2
Assets
Derivative Assets	41
Foreign Exchange Contract | Other Current Liabilities | Designated as Hedging Instrument
Liabilities
Derivative Liabilities		145
Foreign Exchange Contract | Other Current Liabilities | Designated as Hedging Instrument | Level 2
Liabilities
Derivative Liabilities	585
Foreign Exchange Contract | Other Current Liabilities | Not Designated as Hedging Instrument
Liabilities
Derivative Liabilities		0
Foreign Exchange Contract | Other Current Liabilities | Not Designated as Hedging Instrument | Level 2
Liabilities
Derivative Liabilities	436
Interest Rate Swap | Other Current Liabilities | Designated as Hedging Instrument
Liabilities
Derivative Liabilities	9,071	5,203
Interest Rate Swap | Other Current Liabilities | Designated as Hedging Instrument | Level 1
Liabilities
Derivative Liabilities	0	0
Interest Rate Swap | Other Current Liabilities | Designated as Hedging Instrument | Level 2
Liabilities
Derivative Liabilities	$ 9,071	$ 5,203

DERIVATIVES AND FAIR VALUE ME_5

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Narrative) (Details)	Jun. 15, 2018USD ($)	Jun. 29, 2019USD ($)	Mar. 30, 2019USD ($)	Aug. 31, 2018USD ($)swap
Term Loan
Derivative [Line Items]
Face amount of debt	$ 350,000,000
Debt outstanding		$ 332,500,000
Revolving Credit Facility
Derivative [Line Items]
Maximum borrowing capacity	$ 350,000,000
Debt outstanding		$ 105,000,000
Revolving Credit Facility | LIBOR | Minimum
Derivative [Line Items]
Interest rate	1.13%
Revolving Credit Facility | LIBOR | Maximum
Derivative [Line Items]
Interest rate	1.75%
Foreign Exchange Contract
Derivative [Line Items]
Percentage of sales generated outside the US		34.40%
Maturity period for foreign currency contracts		1 year
Cash Flow Hedging | Interest Rate Swap
Derivative [Line Items]
Number of instruments held | swap				2
Derivative fixed interest rate				2.80%
Notional amount				$ 241,900,000
Cash Flow Hedging | Interest Rate Swap | LIBOR
Derivative [Line Items]
Debt exposed to interest rate risk				70.00%
Derivative fixed interest rate				4.05%
Designated as Hedging Instrument | Foreign Exchange Contract
Derivative [Line Items]
Deferred income tax expense (benefit)		$ 0
Designated as Hedging Instrument | Foreign Exchange Contract
Derivative [Line Items]
Designated foreign currency hedge contracts outstanding		66,400,000	$ 81,500,000
Designated as Hedging Instrument | Cash Flow Hedging
Derivative [Line Items]
Gain (loss) to be reclassified within the next twelve months		700,000
Designated as Hedging Instrument | Interest Rate Swap | Interest and other expense, net
Derivative [Line Items]
Amount of Gain (Loss) Recognized in Accumulated Other Comprehensive Loss		(4,292,000)
Not Designated as Hedging Instrument | Foreign Exchange Contract
Derivative [Line Items]
Non-designated foreign currency hedge contracts outstanding		82,100,000	$ 37,400,000
Amount of Gain (Loss) Recognized in Accumulated Other Comprehensive Loss		$ 0

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - Product Recall 1 $ in Millions	3 Months Ended
	Jun. 29, 2019USD ($)
Loss Contingencies [Line Items]
Loss in period	$ 1.9
Customer Returns and Inventory Reserves
Loss Contingencies [Line Items]
Loss in period	0.1
Customer Claims
Loss Contingencies [Line Items]
Loss in period	$ 1.8

SEGMENT AND ENTERPRISE-WIDE I_3

SEGMENT AND ENTERPRISE-WIDE INFORMATION (Details) $ in Thousands	3 Months Ended
	Jun. 29, 2019USD ($)segment	Jun. 30, 2018USD ($)	Mar. 30, 2019USD ($)
Segment Reporting [Abstract]
Number of business units | segment	3
Segment Reporting Information [Line Items]
Net revenues before foreign exchange impact	$ 235,946	$ 224,953
Effect of exchange rates	(2,361)	69
Net revenues	238,451	229,347
Effect of exchange rates	2,769	3,055
Impairment of assets and related costs	(51,166)	(21,170)
Amortization	5,974	6,300
PCS2 accelerated depreciation and related costs	(5,528)	(3,939)
Restructuring and turnaround costs	(2,027)	(3,349)
Other	(33)	(675)
Operating (loss) income	(13,302)	5,293
Total long-lived assets	276,748		$ 343,979
United States
Segment Reporting Information [Line Items]
Net revenues	156,375	142,140
Japan
Segment Reporting Information [Line Items]
Net revenues	15,467	17,389
Europe
Segment Reporting Information [Line Items]
Net revenues	36,753	39,002
Asia
Segment Reporting Information [Line Items]
Net revenues	28,641	29,395
Other
Segment Reporting Information [Line Items]
Net revenues	1,215	1,421
Service
Segment Reporting Information [Line Items]
Net revenues before foreign exchange impact	4,866	4,325
Plasma products and services
Segment Reporting Information [Line Items]
Net revenues	129,745	116,903
Blood Center products and services
Segment Reporting Information [Line Items]
Net revenues	59,907	64,483
Hospital products and services
Segment Reporting Information [Line Items]
Net revenues	48,799	47,961
Plasma
Segment Reporting Information [Line Items]
Net revenues before foreign exchange impact	110,763	99,290
Total long-lived assets	168,816		209,827
Blood Center
Segment Reporting Information [Line Items]
Net revenues before foreign exchange impact	77,996	79,818
Total long-lived assets	88,560		110,073
Hospital
Segment Reporting Information [Line Items]
Net revenues before foreign exchange impact	47,187	45,845
Total long-lived assets	19,372		24,079
Other
Segment Reporting Information [Line Items]
Total long-lived assets	0		$ 0
Operating Segments
Segment Reporting Information [Line Items]
Operating (loss) income	110,360	98,721
Operating Segments | Plasma
Segment Reporting Information [Line Items]
Operating (loss) income	53,725	41,921
Operating Segments | Blood Center
Segment Reporting Information [Line Items]
Operating (loss) income	37,719	38,472
Operating Segments | Hospital
Segment Reporting Information [Line Items]
Operating (loss) income	18,916	18,328
Corporate
Segment Reporting Information [Line Items]
Corporate expenses	$ (61,703)	$ (61,050)

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 29, 2019	Jun. 30, 2018
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance as of March 30, 2019	$ (30,380)
Other comprehensive income (loss) before reclassifications	(3,425)
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	(193)
Net current period other comprehensive income (loss)	(3,618)	$ (4,719)
Balance as of June 29, 2019	(33,998)
Foreign Currency
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance as of March 30, 2019	(25,513)
Other comprehensive income (loss) before reclassifications	195
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	0
Net current period other comprehensive income (loss)	195
Balance as of June 29, 2019	(25,318)
Defined Benefit Plans
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance as of March 30, 2019	(527)
Other comprehensive income (loss) before reclassifications	0
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	0
Net current period other comprehensive income (loss)	0
Balance as of June 29, 2019	(527)
Net Unrealized Gain/Loss on Derivatives
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance as of March 30, 2019	(4,340)
Other comprehensive income (loss) before reclassifications	(3,620)
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	(193)
Net current period other comprehensive income (loss)	(3,813)
Balance as of June 29, 2019	$ (8,153)